Repetitive dosing of SSL-DXR alters tumor vascular permeability, increasing tumor uptake and decreasing clearance in a rat brain tumor model.
No takes yet. Share an insight, caveat, or question.
Repetitive SSL-DXR dosing may enhance tumor delivery in rat models; leaves open clinical translation and safety in humans.
Arnold et al. (2005) studied this question.
Synapse has enriched one closely related paper. Consider it for comparative context: